Helix Opco LLC
Latest From Helix Opco LLC
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Our 12th annual analysis reveals both an expansion of historical patterns of Series A financings and the emergence of a new group of heavily committed, relatively short-term investors.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Start-ups raised $2.57 billion in Q3. Biopharma companies penned 23 alliances; 11 acquisitions were signed, none in the diagnostics industry.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Laboratory Testing Services
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Helix Opco LLC
- Senior Management
Robin Thurston, CEO
James Lu, MD, PhD, Co-founder & SVP, Applied Genomics
Justin Kao, Co-founder & SVP, BD
Scott Burke, Co-founder & CTO
Deena Bahri, Chief Marekting Officer
Philippe Lyko, VP, Finance
David Yu, VP, Product
Jim Chou, VP, Engineering
Will Lee, PhD, VP, Bioinformatics
David Becker, PhD, VP, Lab Ops
Marc Laurent, VP, Ops
Gloria Lee, PhD, Director, Reg & QA
- Contact Info
Helix Opco LLC
Phone: (844) 211-2070
San Carlos, CA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.